BTIG Research downgraded Tactile Systems from Buy to Neutral
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 11/5/2024 | Outperform → Perform | Oppenheimer | |
| 11/5/2024 | Buy → Neutral | BTIG Research | |
| 9/26/2024 | $23.00 | Buy | B. Riley Securities |
10-Q - TACTILE SYSTEMS TECHNOLOGY INC (0001027838) (Filer)
8-K - TACTILE SYSTEMS TECHNOLOGY INC (0001027838) (Filer)
10-Q - TACTILE SYSTEMS TECHNOLOGY INC (0001027838) (Filer)
MINNEAPOLIS, Nov. 04, 2024 (GLOBE NEWSWIRE) -- Tactile Systems Technology, Inc. ("Tactile Medical"; the "Company") (NASDAQ:TCMD), a medical technology company providing therapies for people with chronic disorders, today reported financial results for the third quarter ended September 30, 2024 and announced the adoption of a share repurchase program. Third Quarter 2024 Summary & Recent Business Highlights: Total revenue increased 5% year-over-year to $73.1 million Lymphedema product revenue increased 4% over Q3 2023Airway clearance product revenue increased 10% over Q3 2023 Net income of $5.2 million versus $22.3 million in Q3 2023Adjusted EBITDA of $10.7 million versus $7.7 million in Q3
MINNEAPOLIS, Oct. 21, 2024 (GLOBE NEWSWIRE) -- Tactile Systems Technology, Inc. ("Tactile Medical"; the "Company") (NASDAQ:TCMD), a medical technology company providing therapies for people with chronic disorders, today announced that third quarter of fiscal year 2024 financial results will be released after the market closes on Monday, November 4, 2024. Management will host a conference call with a question and answer session at 5:00 p.m. Eastern Time on November 4, 2024, to discuss the results of the quarter. Those who would like to participate may dial 877-407-3088 (201-389-0927 for international callers) and provide access code 13748661. A live webcast of the call will also be provide
MINNEAPOLIS, Aug. 05, 2024 (GLOBE NEWSWIRE) -- Tactile Systems Technology, Inc. ("Tactile Medical"; the "Company") (NASDAQ:TCMD), a medical technology company providing therapies for people with chronic disorders, today reported financial results for the second quarter ended June 30, 2024. Second Quarter 2024 Highlights: Total revenue increased 7% year-over-year to $73.2 million Lymphedema product revenue increased 8% year-over-yearAirway clearance product revenue increased 2% year-over-year Net income of $4.3 million versus a net loss of $0.1 million in Q2 2023Adjusted EBITDA of $9.1 million versus $6.1 million in Q2 2023Operating cashflow of $13.1 million, ended Q2 2024 with $73.6 mill
Oppenheimer downgraded Tactile Systems from Outperform to Perform
BTIG Research downgraded Tactile Systems from Buy to Neutral
B. Riley Securities initiated coverage of Tactile Systems with a rating of Buy and set a new price target of $23.00
The Company continues to expect full year 2024 total revenue in the range of $300 million to $305 million, representing growth of approximately 9% to 11% year-over-year, compared to total revenue of $274.4 million in 2023.
Tactile Systems Tech (NASDAQ:TCMD) reported quarterly losses of $(0.05) per share which beat the analyst consensus estimate of $(0.11) by 54.55 percent. This is a 66.67 percent decrease over losses of $(0.03) per share from the same period last year. The company reported quarterly sales of $61.088 million which beat the analyst consensus estimate of $59.175 million by 3.23 percent. This is a 3.81 percent increase over sales of $58.846 million the same period last year.
MINNEAPOLIS, Nov. 04, 2024 (GLOBE NEWSWIRE) -- Tactile Systems Technology, Inc. ("Tactile Medical"; the "Company") (NASDAQ:TCMD), a medical technology company providing therapies for people with chronic disorders, today reported financial results for the third quarter ended September 30, 2024 and announced the adoption of a share repurchase program. Third Quarter 2024 Summary & Recent Business Highlights: Total revenue increased 5% year-over-year to $73.1 million Lymphedema product revenue increased 4% over Q3 2023Airway clearance product revenue increased 10% over Q3 2023 Net income of $5.2 million versus $22.3 million in Q3 2023Adjusted EBITDA of $10.7 million versus $7.7 million in Q3
MINNEAPOLIS, Oct. 21, 2024 (GLOBE NEWSWIRE) -- Tactile Systems Technology, Inc. ("Tactile Medical"; the "Company") (NASDAQ:TCMD), a medical technology company providing therapies for people with chronic disorders, today announced that third quarter of fiscal year 2024 financial results will be released after the market closes on Monday, November 4, 2024. Management will host a conference call with a question and answer session at 5:00 p.m. Eastern Time on November 4, 2024, to discuss the results of the quarter. Those who would like to participate may dial 877-407-3088 (201-389-0927 for international callers) and provide access code 13748661. A live webcast of the call will also be provide
MINNEAPOLIS, Oct. 02, 2024 (GLOBE NEWSWIRE) -- Tactile Systems Technology, Inc. ("Tactile Medical"; the "Company") (NASDAQ:TCMD), a medical technology company providing therapies for people with chronic disorders, today announced that Nimbl, its next-generation pneumatic compression platform, is now commercially available throughout the United States for the treatment of upper extremity lymphedema. Nimbl, which is significantly smaller and lighter than previous device iterations, is indicated as a treatment option for patients with both upper and lower extremity lymphedema, chronic edema, venous insufficiency, and wound healing. Nimbl received U.S Food & Drug Administration (FDA) 510(k) cl
4 - TACTILE SYSTEMS TECHNOLOGY INC (0001027838) (Issuer)
4 - TACTILE SYSTEMS TECHNOLOGY INC (0001027838) (Issuer)
4 - TACTILE SYSTEMS TECHNOLOGY INC (0001027838) (Issuer)
SC 13G/A - TACTILE SYSTEMS TECHNOLOGY INC (0001027838) (Subject)
SC 13G - TACTILE SYSTEMS TECHNOLOGY INC (0001027838) (Subject)
SC 13G - TACTILE SYSTEMS TECHNOLOGY INC (0001027838) (Subject)
PHILADELPHIA, Nov. 08, 2023 (GLOBE NEWSWIRE) -- LifeLens Technologies, Inc. (LifeLens), a medical technology company that provides real-time physiological monitoring, today announced the appointment of three industry veterans to the following positions on its executive leadership team and Board of Directors: Daniel J. Sullivan, Chairman of the Board of LifeLens, as Chief Executive OfficerBrent A. Moen as Chief Financial OfficerRichard J. Buchholz as a member of the Board of Directors "With LifeLens, we have a significant opportunity to disrupt healthcare and make a meaningful impact on patients and healthcare professionals, and we are thrilled to have Brent and Rick join the LifeLens tea
MINNEAPOLIS, Oct. 02, 2023 (GLOBE NEWSWIRE) -- Tactile Systems Technology, Inc. ("Tactile Medical") (NASDAQ:TCMD), a medical technology company providing therapies for people with chronic disorders, today announced the appointment of Vindell Washington, M.D. to the Company's Board of Directors ("Board"), effective October 2, 2023. "We are pleased to welcome Dr. Washington to Tactile Medical, who joins our Board with over 30 years of experience in the healthcare industry," said Bill Burke, Chairman of the Board of Tactile Medical. "We will benefit from his breadth of experience in medicine, technology and policy, as well as his expertise in advising healthcare companies on their clinical s
MINNEAPOLIS, July 18, 2023 (GLOBE NEWSWIRE) -- Tactile Systems Technology, Inc. ("Tactile Medical") (NASDAQ:TCMD), a medical technology company providing therapies for people with chronic disorders, today announced the appointment of Sherri Ferstler to the position of Senior Vice President of Sales, effective July 31, 2023. Ms. Ferstler will succeed Eric Pauls, who will be resigning from the Company, effective July 28, 2023. "Sherri is a strategic leader with over 25 years of experience in the healthcare industry and a successful history of developing and leading high-performance teams at scale," said Dan Reuvers, President and Chief Executive Officer of Tactile Medical. "Sherri brings ex